Index

Symbols
3D motifs 597
3D search motifs 597

A
absorption, distribution, metabolism, and excretion (ADME) 4
acyl carrier protein (ACP) domain 382, 393
acyltransferase (AT) domain 382, 384, 386, 388, 389, 390, 396
adhesion phenomena 600
adjusted rand index (ARI) 175
all-atom representation (AAR) model 584, 585
Allegro algorithm 173
allele-specific PCR 4
Alliance for Cellular Signaling (AfCS) 337, 340, 341, 342, 343, 344, 345, 349, 351, 352, 354
amino acids 481, 584, 585, 587, 595, 596
apolipoprotein E (ApoE) 83, 120, 126
Arabidopsis thaliana 512, 530
artificial intelligence (AI) 87, 88
attractors 582
average-linkage clustering 251
axon guidance 628, 644

B
backward genotype-trait association (BGTA) 133, 145
bacteria 533, 534, 535, 536, 537, 546, 547, 548
bacterial pathogenesis 534
bacterial populations 533, 534, 535, 536, 537
basis pursuit 511, 513, 514, 515, 516, 517, 518, 529, 531, 532
Bayesian epistasis association mapping (BEAM) 133
Bayesian information criterion (BIC) 251
biclustering algorithms 148, 149, 151, 152, 158, 159, 161, 170, 171, 172, 174, 175, 176, 177, 178, 180, 185
binding sites-based pharmacophore models 38
bioactive molecules 29, 48, 60
biobanking projects 2
biobanks 2, 8, 9, 11, 12, 18, 20, 22, 24, 26
BioCarta pathway database 373, 379
biochemical fingerprint 3
bioethics 1, 2, 8, 13, 18, 24, 26
bioinformatics 61, 62, 63, 65, 66, 67, 68, 69, 70, 71
bioinformatics datasets 225
biomarker 79, 80, 83, 84, 85, 86, 87, 89, 90, 91, 94, 95, 96, 99, 104, 105, 107, 110, 225, 226, 230, 239, 242
Biomolecular Interaction Network Database (BIND) 135, 136
Biomolecular Object Network Database (BOND) 136
Botrytis cinerea 513
Brownian diffusion 644
Brownian motion 632, 634, 642, 643

C

Copyright © 2011, IGI Global. Copying or distributing in print or electronic forms without written permission of IGI Global is prohibited.
<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>canonical pathways</td>
<td>232, 233, 234</td>
</tr>
<tr>
<td>Carr-Purcell-Meiboom-Gill (CPMG) experiments</td>
<td>97</td>
</tr>
<tr>
<td>casein kinase II (CK2)</td>
<td>41, 42, 58</td>
</tr>
<tr>
<td>causal networks</td>
<td>512, 532</td>
</tr>
<tr>
<td>cell adhesion</td>
<td>599, 600, 622, 625, 626</td>
</tr>
<tr>
<td>cell ligands</td>
<td>599, 600, 602, 603, 605, 606, 610, 613, 618, 620, 626</td>
</tr>
<tr>
<td>cell motility</td>
<td>628, 644</td>
</tr>
<tr>
<td>cells</td>
<td>600, 603, 604, 605, 622, 623, 624, 626, 629, 631, 642, 644, 645</td>
</tr>
<tr>
<td>cells receptors</td>
<td>599, 600, 602, 603, 604, 605, 606, 610, 613, 615, 618, 620, 626</td>
</tr>
<tr>
<td>cellular machinery</td>
<td>337</td>
</tr>
<tr>
<td>cellular networks</td>
<td>481</td>
</tr>
<tr>
<td>cellular nucleus</td>
<td>481, 507</td>
</tr>
<tr>
<td>centers for disease control and prevention (CDC)</td>
<td>62</td>
</tr>
<tr>
<td>centrality index</td>
<td>252</td>
</tr>
<tr>
<td>centroids</td>
<td>583, 585, 597, 598</td>
</tr>
<tr>
<td>chemical cues</td>
<td>629</td>
</tr>
<tr>
<td>chemical cues, attractive</td>
<td>629</td>
</tr>
<tr>
<td>chemical cues, repulsive</td>
<td>629</td>
</tr>
<tr>
<td>chemotactic assay</td>
<td>630, 644</td>
</tr>
<tr>
<td>chemotactic cues</td>
<td>628</td>
</tr>
<tr>
<td>chemotactic guidance mechanisms</td>
<td>629</td>
</tr>
<tr>
<td>chemotaxis</td>
<td>629, 642, 643, 644</td>
</tr>
<tr>
<td>chemotherapy</td>
<td>407, 423, 424</td>
</tr>
<tr>
<td>Cheng and Church Algorithm (CC-Algorithm)</td>
<td>160, 161, 163</td>
</tr>
<tr>
<td>Chromatin Immunoprecipitation (ChIP)</td>
<td>158, 180, 185</td>
</tr>
<tr>
<td>Cholesterol Ester Transfer Proteins (CETPs)</td>
<td>297</td>
</tr>
<tr>
<td>Denaturing High-Performance Liquid Chromatography (DHPLC)</td>
<td>4, 26</td>
</tr>
<tr>
<td>Cheng and Church Algorithm (CC-Algorithm)</td>
<td>160, 161, 163</td>
</tr>
<tr>
<td>Cholesteryl Ester Transfer Proteins (CETPs)</td>
<td>297</td>
</tr>
<tr>
<td>Chromatin Immunoprecipitation (ChIP)</td>
<td>158, 180, 185</td>
</tr>
<tr>
<td>cleavable ICAT (cICAT)</td>
<td>94</td>
</tr>
<tr>
<td>Clique Percolation Method (CPM)</td>
<td>255, 256</td>
</tr>
<tr>
<td>clonal bacterial population</td>
<td>548</td>
</tr>
<tr>
<td>COALESCE Algorithm</td>
<td>173</td>
</tr>
<tr>
<td>collision induced dissociation (CID)</td>
<td>92</td>
</tr>
<tr>
<td>colorectal cancer (CRC)</td>
<td>372</td>
</tr>
<tr>
<td>commonality of functional annotation method (CFA)</td>
<td>137</td>
</tr>
<tr>
<td>complete-linkage clustering</td>
<td>251</td>
</tr>
<tr>
<td>complimentary DNA (cDNA)</td>
<td>206</td>
</tr>
<tr>
<td>conformation sensitive gel electrophoresis</td>
<td>4, 22</td>
</tr>
<tr>
<td>Conserved Domain Architectural Retrieval Tool (CDART)</td>
<td>210</td>
</tr>
<tr>
<td>content management system (CMS)</td>
<td>324, 326, 327, 336</td>
</tr>
<tr>
<td>copy number polymorphisms (CNPs)</td>
<td>119</td>
</tr>
<tr>
<td>copy number variants (CNVs)</td>
<td>118, 119, 122</td>
</tr>
<tr>
<td>Coupled two-way clustering (CTWC)</td>
<td>171</td>
</tr>
<tr>
<td>Crohn’s disease (CD)</td>
<td>121</td>
</tr>
<tr>
<td>cross validation (CV)</td>
<td>88</td>
</tr>
<tr>
<td>cubic spline interpolation</td>
<td>513, 516</td>
</tr>
<tr>
<td>curse of dimensionality</td>
<td>408, 409</td>
</tr>
<tr>
<td>curse of sparsity</td>
<td>408</td>
</tr>
<tr>
<td>cystic fibrosis</td>
<td>4</td>
</tr>
<tr>
<td>cytokine</td>
<td>339, 340, 345, 346, 347, 349, 350, 352, 353</td>
</tr>
<tr>
<td>cytology</td>
<td>599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 612, 613, 615, 616, 617, 618, 620, 621, 622, 623, 624, 625, 626, 629, 631, 642, 644, 645</td>
</tr>
<tr>
<td>cytosine-phosphate-guanine (CpG)</td>
<td>429, 432, 434, 435, 439, 443, 448, 450, 451, 452, 453</td>
</tr>
<tr>
<td>cytoskeleton proteins</td>
<td>29</td>
</tr>
<tr>
<td>cytoskeleton rearrangement</td>
<td>628</td>
</tr>
</tbody>
</table>

**D**

<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Database of Interacting Proteins (DIP)</td>
<td>135, 136</td>
</tr>
<tr>
<td>data dimensionality</td>
<td>406, 408, 409</td>
</tr>
<tr>
<td>data-driven objective (DDO)</td>
<td>228</td>
</tr>
<tr>
<td>datasets, meta-analysis of</td>
<td>408, 427</td>
</tr>
<tr>
<td>data topology</td>
<td>406, 408</td>
</tr>
<tr>
<td>DCRR Web server</td>
<td>583, 586, 587, 596</td>
</tr>
<tr>
<td>dehydratase (DH) domain</td>
<td>382, 388</td>
</tr>
<tr>
<td>dideoxy sequencing</td>
<td>83</td>
</tr>
<tr>
<td>differential gel electrophoresis (DIGE)</td>
<td>92</td>
</tr>
<tr>
<td>differentially methylated regions (DMR)</td>
<td>193</td>
</tr>
<tr>
<td>directed acyclic graph (DAG)</td>
<td>319, 323</td>
</tr>
</tbody>
</table>
disease-disease associations 275, 276, 277, 284, 285, 290
disease gene prediction 281

disease ontology (DO) 323
distance weighted discrimination (DWD) 87
DNA damage sensing 479, 484
DNA methylation 187, 192, 193, 194, 195, 196, 199
DNA microarray data analysis 148, 149, 179, 185
DNA microarrays 5, 148, 149, 150, 151, 152, 157, 176, 179, 180, 184, 185, 186, 406, 407, 408, 409, 410, 414, 416, 420, 424, 426
DNA repair 478, 479, 482, 483, 484, 485, 499, 500, 501, 502, 503, 504, 505, 506, 509, 510
DNA repair proteins 29
DNA replication 370
DNA sequencing 4, 23, 187, 188, 190, 191, 192, 193, 194, 196, 197, 201
docking 30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 45, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
docking domain 404
double-centroid reduced representation (DCRR) model 583, 584, 585, 586, 587, 588, 589, 590, 591, 595, 596
double-centroid representation 598
double strand breaks (DSB) 479
drift 644
dynamic causal modeling (DCM) 511, 513, 517, 518, 519, 529, 532

efficacy biomarkers 80
Electron capture dissociation (ECD) 92
electronic health records (EHR) 8, 26
Electronic medical records (EMRs) 14
electron transfer dissociation (ETD) 92
embryonic stem (ES) cell 188, 192, 201
embryos 629
energy landscapes 572, 573, 576, 579, 580, 581, 582
enoylreductase (ER) domain 382, 387
epidemic bacterial population 548
epigenetics 187, 195, 196, 200, 201, 379
eukaryotic cell movements 631
eukaryotic cells 481, 507
evolutionary accessibility 572, 579
evolutionary conserved regions (ECRs) 137
expression quantitative trait loci (eQTLs) 120, 121
Extended Dimension Iterative Signature Algorithm (EDISA) 167, 185
extended Kalman filters 478, 490, 491, 505
extracellular ligand concentration 628
extracellular ligands 628, 629
extracellular matrix (ECM) 599, 600, 601, 605, 606, 607, 608, 609, 610, 612, 613, 620, 621

f

fitness landscape 582
flexible overlapping biclustering (FLOC) 161, 172, 175
focal contacts 600
focused interaction testing framework (FITF) 133

functional linkage gene network (FLN) 275, 276, 277, 278, 279, 280, 281, 282, 283, 285, 286
functional phenotypes 337, 339

G

gene expression 379
gene expression omnibus (GEO) 228, 232, 242
gene expression profiles (GEP) 407, 409, 412, 413, 415
gene networks 275, 276, 279, 284, 286, 287, 289
gene octology (GO) pathway database 373, 379, 407, 415, 416, 418, 425
gene ontologies (GO) 134, 135, 136, 139, 144, 157, 158, 182, 186, 259, 260, 279, 319, 322, 323, 324, 407, 415, 416, 418, 425
genes 511, 513, 514
gene set enrichment analysis (GSEA) 258, 264, 265, 299, 300, 301, 302, 373, 374
gene signatures 415, 427
genetic aberrations 369, 370, 371, 373, 375, 376
genetic algorithms (GA) 33, 34, 582
Genetic Association Database (GAD) 136
genetic drift 548
genetic privacy 14, 19
genome analysis 397, 404
genome mining 404
genomes 380, 381, 384, 385, 387, 388, 391, 392, 396, 397, 400, 401, 404, 405
genome-wide association studies (GWAS) 114, 115, 116, 117, 118, 119, 120, 121, 122, 127, 128, 129, 130, 131, 132, 133, 134, 137, 138, 139, 140, 141, 147, 299, 331
genome-wide genotyping 6
genomic revolution 61, 63
Genotype-Tissue Expression (GTEx) 121
Gibbs algorithm 215
G-protein coupled receptors (GPCRs) 29
grammatical evolution neural network (GENN) 133
Granger causality 511, 512, 513, 514, 515, 517, 522, 523, 526, 529, 530, 531, 532
Granger causality, complex 532
Granger causality, conditional 532
Granger causality, partial 532
graphical user interfaces (GUI) 511, 512, 513, 529
Group A Streptococcus (GAS) 67, 68
growth cone 644
guide tree 205, 208, 213

H
Haemophilus b polysaccharide vaccine (HbPV) 64
Health Information Privacy 14
Health Information Technology for Economic and Clinical Health (HITECH) Act 14
Helicobacter pylori 534, 535, 537, 541, 542, 543, 544, 545, 546, 547, 548
hepatitis B surface antigen (HBsAg) 62
hepatitis B virus (HBV) 62
high throughput screening (HTS) 29, 30, 41, 50, 55, 57
homologs 209, 210, 211, 213, 214, 216, 217, 223
host-pathogen interaction 533, 543
hubs 226, 227
human genetics 115
human genome 4, 5, 8, 13
Human Genome Project (HGP) 16
human genome sequence 114
human nervous system 628, 629, 641, 644
Human Protein Reference Database (HPRD) 135, 136
human telomerase RNA 551, 569
hybrid models 505

I
identifiability analysis 493, 506
identity-by-descent (IBD) 118
immunoinformatics 64, 67, 71, 72, 77
infection 533, 534, 535, 536, 539, 541, 542, 543, 544, 545, 547
innate immune systems 429, 432, 442, 443, 449
in silico methods 30
in silico modeling 230
in silico screening 29, 55
integrative approach 159, 160
Integrative Social Contract Theory (ISCT) 15
Interactome 406, 408, 410, 412, 420, 425, 427
isotope-coded affinity tags (ICAT) 94
Iterative Clique Enumeration (ICE) 258, 265
iterative signature algorithm (ISA) 166, 167, 168, 175

K
Kalman filters 478, 480, 490, 491, 497, 499, 504, 505
ketoreductase (KR) domain 382, 388, 390, 391
ketosynthase (KS) domain 382, 385, 386, 390, 391, 393
kinases 29
Index

kinetic accessibility 572, 576, 577, 578, 579
k-means clustering 250, 251, 254
knowledge-driven objective (KDO) 228, 230
Kyoto Encyclopedia of Genes and Genomes (KEGG) 136, 320, 321, 322, 324, 333, 335, 373

L
lactamase beta (Lactb) 121
lamellipods 600
large compound databases 29
leukocyte cells 600, 617, 626
leukocyte rolling 599, 600, 601, 602, 603, 605, 608, 610, 615, 618, 622, 623, 624, 626
ligand 339, 340, 341, 343, 344, 345, 346, 347, 348, 353
ligand based virtual screening (LBVS) 30, 43, 45, 48, 49, 50, 51
ligand binding sites (LBS) 583, 584, 586, 591, 595, 596, 597, 598
ligand flexibility 31
ligand-gated ion channels (LGICs) 29
ligand-receptor binding 630, 636
ligand-receptor connections 626
ligand-receptor molecular connections 599
ligand-receptor pairs 601, 602, 623
linkage disequilibrium (LD) 137, 138, 139
lipoprotein lipase (Lpl) 121
liposomes 600
local field potential (LFP) data 513, 526, 529

M
macrophages, Myd88 428, 429, 430, 436, 437, 438, 439, 441, 442
macrophages, Trif 428, 429, 430, 437, 438, 439
macrophages, wild-type 428, 430, 438
MALDI-TOF mass spectrometry 4, 24
mammalian phenotype ontology (MP) 323
mammalian sterile 20-like (MST-like) 356
mammalian target of rapamycin (mTOR) 237, 238, 245
MAPK kinase kinase (MAP3K) 355, 356, 357, 365
MAPK kinase (MAP2K) 355, 356, 357, 360, 361
MAPK Pathways 357, 362
Markov chains 630, 643, 644
Markov Clustering (MCL) 257, 258, 259
massive genetic code 203
MATLAB 583, 584, 586, 595, 596
Maturity Onset Diabetes of the Young (MODY) 295
maximum dimension set (MDS) 161
mechanistic approach 84
Mendelian traits 114
messenger RNA (mRNA) 404, 481, 482, 484, 485, 493, 498, 503, 507
meta-analysis 228, 236, 243
metastatic relapse 406, 407, 410, 412, 418, 422, 427
Michaelis-Menten kinetics 360
microarray datasets 428, 429, 430, 432, 438, 442
microfluidic cell array (MCA) 533, 536, 538, 539, 540, 541, 543, 544, 545
microfluidics 535, 548
microRNA (miRNA) 230, 232, 241
microtubule 645
microtubule-associated protein tau (MAPT) 120, 125
minor allele frequency (MAF) 118, 119
modern molecular medicine 2
modularity 248, 249, 253, 254, 255, 264, 266, 267, 268, 271
molecular analysis 3
molecular bonds 599, 600, 613, 617, 620
molecular characterization approach 3
molecular complex detection (MCODE) 257, 258, 259, 266
molecular dynamics (MD) simulations 34, 35, 40, 42
molecular dynamics simulation 582
molecular Interaction database (MINT) 135, 136
molecular mechanics/Poisson-Boltzmann surface area (MMPBSA) 40
molecular operating environment (MOE) 39
molecular profiling platform 5
Monte Carlo (MC) simulations 33, 34, 40
mouse genome informatics (MGI) 323
multilocus sequence typing (MLST) 69
multiple sequence alignment (MSA) 208, 213
multiplexed amplification coupled mini-sequencing 4
multiscale 628, 645
multi-scale biological structure 2
multi-tiered approach 316, 317

N
National Cancer Institute (NCI) 320
National Center for Biotechnology Information (NCBI) 323
National Institute for Allergy and Infectious Diseases (NIAID) 69
National Library of Medicine (NLM) 323
Nature Publishing Group (NPG) 320
NCBI EntrezGene database 407, 410, 416, 418
NCBI's BLAST 203
neural cell adhesion molecule (N-CAM) 632
neural networks (NN) 88
neuron migration 628
neurons 628, 644
neurons, axonal projections 628, 629, 630, 631, 632, 641, 642, 643, 644
neurons, filopodia 630, 643
neurons, growth cones (GC) 628, 629, 630, 631, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644
neurons, receptors 628, 629, 630, 631, 632, 633, 635, 636, 637, 638, 639, 641, 642
new enhanced reverse vaccinology environment (NERVE) 69, 71, 76
new generation of sequencing (NGS) technology 370
nicotinic acid adenine dinucleotide phosphate (NAADP) 49, 56
NJW algorithm 254
non-coding RNA (ncRNA) 550, 551, 552, 553, 556, 557, 565, 566, 569, 571
non-integrative approach 160
non-peptidic compounds 28
non-ribosomal peptides 404
nonribosomal peptide synthetases (NRPS) 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 393, 395, 396, 397, 398, 400, 402, 404
non-small cell lung cancer (NSCLC) 236, 237, 372
nuclear receptors (NRs) 29
nucleosome 187, 188, 189, 190, 191, 193, 194, 195, 196, 197, 198, 199, 200, 201
nucleosome-free region (NFR) 189
nucleotide excision repair (NER) 478, 479, 482, 483, 484, 485, 487, 488, 489, 493, 494, 495, 496, 498, 499, 500, 506, 509, 510

O
oligonucleotide ligation 4, 19
omics 79, 80, 99
oncogenes 370, 408
Online Mendelian Inheritance in Man (OMIM) database 281, 282, 288
ontology lookup service (OLS) 323
ontology report 324, 325, 328
order preserving submatrix (OPSM) 156, 164, 165, 166, 175
ordinary differential equation (ODE) 481, 482, 483, 485, 487, 489
outer hair cell (OHC) 207

P
p21 Ras-activated protein kinase (PAK-like) 356
PAM2Cys-SKKKK (PAM2) 429, 432, 433, 434, 435, 439, 440, 442, 448, 460, 461, 462, 463, 464
PAM3Cys-SKKK (PAM3) 429, 432, 434, 435, 439, 440, 442, 448, 464, 465, 466, 467, 468, 469, 470
panmictic bacterial population 548
paralogs 205, 207, 209, 210, 217, 218
partial least-squares (PLS) 345
pathfinding 629
pathogens 428, 429
pathway based analyses (PBA) 137
pathway databases 373, 374
pathway interaction database (PID) 320, 335, 373, 379
pathway ontology (PW) 317, 319, 320, 322, 323, 324, 325, 327, 333
pathways 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379
personal genome project (PGP) 6
personalized medicine 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 18, 20, 25
personalized medicine coalition 3
personalized medicine paradigm shift 11
Pervical’s Medical Ethics 9
pharmacogenetics 3, 4, 21, 27
pharmacogenomics 2, 3, 4, 5, 8, 11, 14, 16, 17, 23, 24, 25, 27
pharmacophore 596, 597, 598
pharmacophore modeling 598
phosphatases 29
platelet activating factor (PAF) 339, 340, 343, 344, 346, 354
Polycomb response elements (PRE) 191
Poly I:C 429, 432, 433, 434, 435, 439, 448
polyketides 381, 399, 404
polyketide syntheses (PKS) 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 393, 394, 395, 396, 397, 398, 400, 402, 404, 405
polyketide syntheses, type I 405
polyketide syntheses, type II 405
polymerase chain reaction (PCR) 206
post-translational modifications (PTMs) 135
potential of mean force (PMF) 39, 42, 56
predictive approach 84
primary protein sequence 202
principal components analysis (PCA) 341, 371, 372
privacy by design (PbD) 16, 27
proapoptotic Bax 370
prostaglandin E2 (PGE) 347, 354
protein cleavable-isotope dilution mass spectrometry (PC-IDMS) 95
protein families database (PFAM) 136
protein flexibility 34
protein phosphatase 1-like (Ppm1l) 121
protein phosphorylation markers 337, 339
protein-protein interaction (PPI) 134, 135, 136, 139, 147, 301, 302, 303, 304
protein-protein physical interaction (PPI) 281, 285, 286
proteins 511, 583, 584, 585, 586, 587, 588, 589, 590, 591, 595, 596, 597, 598
protein tyrosine phosphatase-1B (PTP1B) 41
proteomics profiling 6
pseudoknots 550, 551, 552, 553, 555, 557, 562, 564, 566, 568, 569, 570, 571
pseudoknots, recursive simple non-standard 550, 552, 555, 564, 565, 568, 571
pseudoknots, recursive standard 550, 552, 555, 565, 568, 569
pseudoknots, simple non-standard 550, 552, 554, 555, 559, 560, 562, 563, 564, 565, 568, 569, 571
pseudoknots, standard 550, 552, 553, 554, 555, 557, 559, 560, 562, 563, 564, 565, 568, 569, 571
quantitative real-time polymerase chain reaction (qRT-PCR) 90
quantitative structure–activity relationships (QSAR) 43, 47, 48, 50, 56, 57, 58
quantitative trait loci (QTL) 137, 323
quantum dot (QD) imaging technique 631
rapamycin analogs (Rapalogs) 237
ras pathway 372
rat genome database (RGD) 316, 317, 319, 320, 323, 324, 325, 327, 328, 329, 333, 334
RB gene 370
receptor 339, 346, 347, 353
receptor redistribution 628, 630, 641
recursive partitioning method (RPM) 133
reduced representation 583, 585, 598
replica exchange molecular dynamics (REMD) 40
resimiquod (R848) 429, 432, 434, 439, 448, 473, 474, 475, 476, 477
reverse engineering 532
Index

reverse vaccinology 63, 64, 65, 66, 67, 69, 76, 77, 78
ribonucleic acid (RNA) 404, 481, 572, 573, 574, 575, 576, 577, 579, 580, 581, 582
robustness 427
root-mean-square deviation (RMSD) 31, 34, 44
rupture phenomenon 599, 609, 626

safety biomarkers 80
sanger sequencing 83, 84
search tool for the retrieval of interacting genes/proteins (STRING) 135, 136, 143
secondary metabolites 380, 405
secondary metabolites, nonribosomal peptide 380, 381, 384, 385, 391, 395, 398, 399, 400, 401, 402, 403, 404
secondary metabolites, polyketide 380, 381, 382, 384, 385, 390, 391, 395, 398, 399, 400, 401, 402, 403, 404
second messengers 337, 339, 341, 343, 347
seeded iterative signature algorithm (SISA) 167, 182
self-organizing map (SOM) 252
self-splicing introns 551
sensitivity analysis 480, 489, 494, 495, 498, 499, 503
sequential evolutionary biclustering (SEBI) 162
severe acute respiratory syndrome (SARS) 62
sickle cell anemia 4
signaling pathways 370, 372, 373, 374, 375, 376, 377
simulation techniques 31, 34
single-linkage clustering 251
single nucleotide polymorphism (SNP) 3, 4, 5, 7, 12, 19, 21, 22, 23, 24, 25, 26, 27, 72, 113, 117, 119, 121, 122, 126, 127, 128, 129, 130, 131, 132, 133, 134, 136, 137, 138, 139, 140, 141, 143, 145, 146, 147
single-strand conformation polymorphism (SSCP) analysis 4, 25
small interfering RNA (siRNA) 122
small open reading frames (SORFs) 93
SNP analysis 4
Social Security Administration (SSA) 16
solid-phase chemical cleavage 4, 19
space 582
space, conformation 574, 576, 582
space, fitness 582
space, folding energy 572, 582
space, genotype 582
state estimation 493, 506
state observer 506
statistical-algorithmic method for bicluster analysis (SAMBA) 171, 175
statistical nonlocality 626
STE20 oxidant stress kinase (SOC-like) 356
stimulate echo (STE) 97
stochastic exploration 31, 34
stochastic fields 626
stochastic field theory 599
streptococcus pyogenes 534, 537
structural alignment 550, 551, 552, 553, 555, 556, 559, 565, 566, 568, 569, 570, 571
structure-based pharmacophore modeling (SBPM) 38, 39, 47
structure-based virtual screening (SBVS) 30, 31, 38, 39, 40, 43, 48, 50, 51
structure-function relationship 202, 207
structures, regular 571
suboptimal attractors 572, 573
substrate channeling 405
sulphate transporter anti-sigma factor antagonist (STAS) 207, 210, 211, 218, 219, 222
super paramagnetic clustering (SPC) 257, 258, 259
support vector machine (SVM) 87, 88, 89, 110, 189
surrogate endpoint biomarker 80
systematic search routines 31
systemic lupus erythmatosus (SLE) 238
systems based theory 63
systems biology 1, 2, 6, 17, 18, 20, 22, 24, 27, 479, 503, 505

T
Tabu Search (TS) methods 33, 34
target engagement biomarkers 80
telomerases 551
temporal sampling 345
tetrahedral motif model 584, 586, 587, 590, 591, 592, 593, 594, 595, 596, 597, 598
TFBS prediction 431, 438, 442, 448
thiotemplate mechanisms 380
toll-like receptors (TLR) 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 446, 449
transcription factor binding sites (TFBS) 214, 429, 430, 431, 435, 436, 437, 438, 439, 440, 442, 443, 448
transcription start sites (TSS) 189, 194
transcript levels 337, 339
transcriptomic biomarkers 84, 89, 90
TRANSPATH pathway database 373
Transport Classification Database (TCDB) 210
trypanothione reductase inhibitors 29
tuned reliefF (TuRF) 138

unified causal model (UCM) 511, 513, 519, 520, 521, 522, 523, 524, 525, 526, 527, 529, 530
unified human interactome (UniHI) 135, 136, 142

vaccines 61, 62, 64, 66, 67, 68, 69, 72, 73, 74, 75, 76, 78
vaccinomics 72, 76, 78
van der Waals (VDW) surface representations 584, 585, 586, 587, 598
vascular endothelial growth factor (VEGF) 321
viral diseases 61
virtual screening (VS) 28, 29, 30, 38, 39, 40, 41, 42, 43, 45, 46, 48, 50, 51, 52, 55, 57, 59
virulence 546, 548
viscoelasticity 627

Watson, James 479
Western Australia (WA) 12
World Health Organization (WHO) 62, 66, 70, 77

xanathine uracil permease (XUP) 207, 210, 211, 218, 219